News

News

February 21, 2017

IMMUNOMEDICS FILES FEDERAL LAWSUIT AGAINST VENBIO FOR CONTINUING MATERIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS

February 17, 2017

IMMUNOMEDICS PRESENTS UPDATED RESULTS WITH SACITUZUMAB GOVITECAN (IMMU-132) IN HEAVILY-PRETREATED PATIENTS WITH METASTATIC UROTHELIAL CANCER

February 15, 2017

IMMUNOMEDICS SENDS LETTER TO STOCKHOLDERS HIGHLIGHTING VALUE CREATING GLOBAL LICENSING AGREEMENT, UNDERSCORING FULFILLMENT OF PROMISE TO STOCKHOLDERS

February 14, 2017

IMMUNOMEDICS COMMENTS ON BASELESS VENBIO LAWSUIT

February 10, 2017

IMMUNOMEDICS ANNOUNCES POSTPONEMENT OF 2016 ANNUAL MEETING

February 10, 2017

Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties

February 9, 2017

IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2017 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

February 9, 2017

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR SECOND QUARTER FISCAL 2017 RESULTS

February 7, 2017

IMMUNOMEDICS STRONGLY ENCOURAGES STOCKHOLDERS TO REJECT THE VENBIO NOMINEES — WITH FOUR NEW INDEPENDENT DIRECTORS AND A ROBUST VALUE-MAXIMIZATION PROCESS, STOCKHOLDERS SHOULD NOT RISK GIVING VENBIO DIRECTORS CONTROL OF THE IMMUNOMEDICS BOARD OF DIRECTORS

February 2, 2017

IMMUNOMEDICS MAILS LETTER TO STOCKHOLDERS HIGHLIGHTING STRENGTH OF NEW BOARD AND DEEP ENGAGEMENT IN ROBUST, VALUE-CREATING STRATEGIC AND CMC PROCESSES

January 30, 2017

IMMUNOMEDICS SETS THE RECORD STRAIGHT IN NEW PRESENTATION

January 27, 2017

IMMUNOMEDICS ISSUES STATEMENT TO STOCKHOLDERS AND FILES INVESTOR PRESENTATION

January 24, 2017

IMMUNOMEDICS MAILS LETTER TO STOCKHOLDERS

January 18, 2017

IMMUNOMEDICS HIGHLIGHTS EXPANDED PIPELINE POSITIONING COMPANY FOR SUSTAINED VALUE CREATION

January 18, 2017

IMMUNOMEDICS ANNOUNCES NEW DATA FOR IMMU-132 AT INVESTOR R&D DAY

January 12, 2017

IMMUNOMEDICS TO MAIL LETTER TO STOCKHOLDERS HIGHLIGHTING UNPRECEDENTED PROGRESS TOWARD ENHANCED VALUE CREATION

January 9, 2017

IMMUNOMEDICS ANNOUNCES ANTITUMOR EFFECT OF SACITUZUMAB GOVITECAN (IMMU-132) IN TRIPLE-NEGATIVE BREAST CANCER CAN BE ENHANCED WITH DNA-REPAIR INHIBITORS

January 9, 2017

IMMUNOMEDICS ANNOUNCES RECONSTITUTED BOARD OF DIRECTORS AND LEADERSHIP SUCCESSION PLAN

January 5, 2017

IMMUNOMEDICS ANNOUNCES INVESTOR R&D DAY ON JANUARY 18, 2017